1. Photobiomodulation therapy prevents dysgeusia chemotherapy induced in breast cancer women treated with doxorubicin plus cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical trial
- Author
-
Ana Paula Negreiros Nunes Alves, Anna Clara Aragão Matos Carlos, Paulo Goberlânio de Barros Silva, Cássia Emanuella Nóbrega Malta, Eveline Fernandes Alves E Silva, Manuele Carine Maciel de Alencar, José Fernando Bastos de Moura, Fábio Figueiredo Chaves, and Victor Bruno Caitano Nogueira
- Subjects
medicine.medical_specialty ,Cyclophosphamide ,Antineoplastic Agents ,Breast Neoplasms ,Dysgeusia ,Placebo ,Gastroenterology ,Cachexia ,Breast cancer ,Weight loss ,Internal medicine ,Mucositis ,Humans ,Medicine ,Low-Level Light Therapy ,business.industry ,medicine.disease ,Clinical trial ,Oncology ,Doxorubicin ,Quality of Life ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC). This is a phase II, randomized, triple-blind, placebo-controlled clinical trial involving 112 breast cancer patients treated with AC. The patients were divided equally into two groups: a test group treated with 2 J red laser and 3 J infrared laser on 21 points that were symmetrically distributed on the tongue on day 0 of four cycles of AC, and an equal placebo group treated with simulated PBMT to blind the patient, evaluator, and statistician. The clinicopathological and sociodemographic data, results of taste test, and subjective taste analysis, and the QoL, ECOG performance status, body mass index, and other side effects were recorded. The data were analyzed using ANOVA-RM/Bonferroni, Friedman/Dunn, and chi-square/Fisher’s exact tests. PBMT patients showed less objective and subjective taste loss (p
- Published
- 2021
- Full Text
- View/download PDF